# EDGAR Filing Document

**Accession Number:** 0002106704
**File Stem:** 0002106704-26-000001
**Filing Date:** 2026-1
**Character Count:** 12603
**Document Hash:** 9b512276452d9956da1d1cadebd42cdd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002106704-26-000001.hdr.sgml**: 20260123

**ACCESSION NUMBER**: 0002106704-26-000001

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260123

**DATE AS OF CHANGE**: 20260123

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AGENUS INC
- **CENTRAL INDEX KEY:** 0001098972
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 061562417
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-60419
- **FILM NUMBER:** 26553495

**BUSINESS ADDRESS:**
- **STREET 1:** 3 FORBES ROAD
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421
- **BUSINESS PHONE:** 781-674-4410

**MAIL ADDRESS:**
- **STREET 1:** 3 FORBES ROAD
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANTIGENICS INC /DE/
- **DATE OF NAME CHANGE:** 19991115
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ZYNEXT VENTURES USA LLC
- **CENTRAL INDEX KEY:** 0002106704

**ORGANIZATION NAME:**
- **EIN:** 923002707
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 73 ROUTE 31, N.
- **CITY:** PENNINGTON
- **STATE:** NJ
- **ZIP:** 08534
- **BUSINESS PHONE:** 6097301900

**MAIL ADDRESS:**
- **STREET 1:** 73 ROUTE 31, N.
- **CITY:** PENNINGTON
- **STATE:** NJ
- **ZIP:** 08534

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**AGENUS INC**

*(Name of Issuer)*

**Common Stock**

*(Title of Class of Securities)*

**00847G804**

*(CUSIP Number)*

**Ravi Yadavar**<br>73 Route 31, North<br>Pennington NJ 08534<br>609-730-1900

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**01/15/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **00847G804** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ZYNEXT VENTURES USA LLC** | Name of reporting person<br>**ZYNEXT VENTURES USA LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2133333.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2133333.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2133333.00** | Aggregate amount beneficially owned by each reporting person<br>**2133333.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.9%** | Percent of class represented by amount in Row (11)<br>**5.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Limited liability company

| **CUSIP No.** | **00847G804** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ZYNEXT VENTURES PTE LTD** | Name of reporting person<br>**ZYNEXT VENTURES PTE LTD** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**U0** | Citizenship or place of organization<br>**U0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2133333.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2133333.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2133333.00** | Aggregate amount beneficially owned by each reporting person<br>**2133333.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.9%** | Percent of class represented by amount in Row (11)<br>**5.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**HC** | Type of Reporting Person (See Instructions)<br>**HC** | |

---

**Comment for Reporting Person:** Private limited company; parent of Zynext Ventures USA LLC.

| **CUSIP No.** | **00847G804** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**ZYDUS LIFESCIENCES LTD** | Name of reporting person<br>**ZYDUS LIFESCIENCES LTD** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**K7** | Citizenship or place of organization<br>**K7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2133333.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2133333.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2133333.00** | Aggregate amount beneficially owned by each reporting person<br>**2133333.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.9%** | Percent of class represented by amount in Row (11)<br>**5.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**HC** | Type of Reporting Person (See Instructions)<br>**HC** | |

---

**Comment for Reporting Person:** Public limited company; parent of Zynext Ventures Pte. Ltd.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock

**(b) Name of Issuer:**
AGENUS INC

**(c) Address of Issuer's Principal Executive Offices:**
3 FORBES ROAD, LEXINGTON, MA, 02421

**Item 4. Purpose of Transaction**

The acquisition of securities of the issuer is part of a strategic collaboration between Zydus and the issuer.  At Zydus?s option, Zydus may appoint either a board observer or board member to issuer?s board of directors so long as Zydus retains significant ownership of issuer?s stock.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentages set forth in row 13 are based on an aggregate of 36,141,682 shares of Common Stock outstanding, consisting of (i) 34,008,349 shares of Common Stock outstanding as of November 7, 2025, as disclosed by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 10, 2025, and (ii) 2,133,333 shares of Common Stock issued to Zydus.

**(b)**
The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.

**(c)**
On January 15, 2026, Zynext Ventures USA LLC (and thus, indirectly, Zynext Ventures Pte Ltd and Zydus Lifesciences Ltd) acquired 2,133,333 shares of Common Stock, at a purchase price of $7.50 per share, pursuant to the transactions contemplated by the Securities Purchase Agreement. Except for the transactions described in this Item 5(c), none of the Reporting Persons has affected any transaction in shares of Common Stock during the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

On June 3, 2025, the issuer entered into three agreements with the Zynext Ventures USA LLC and its affiliates:  1) the Securities Purchase Agreement to purchase the common stock reported on this Schedule 13D, 2) an Asset Purchase Agreement, pursuant to which Zydus?s affiliate agreed to purchase certain manufacturing operations, real estate, equipment, and certain contracts from the issuer in exchange for cash, and 3) a License Agreement, pursuant to which the issuer granted Zydus Lifesciences Ltd an exclusive license to develop, manufacture and commercialize botensilimab and balstilimab in India and Sri Lanka in exchange for a royalty on net sales.  On January 15, 2026, the transactions contemplated by these agreements were closed.  At Zydus?s option, Zydus may appoint either a board observer or board member to issuer?s board of directors so long as Zydus retains significant ownership of issuer?s stock. As part of the Securities Purchase Agreement, the issuer has agreed to prepare and file a registration statement to register the resale of the shares of Common Stock purchased pursuant to the Securities Purchase Agreement within 60 calendar days after the date of the Closing and to use commercially reasonable efforts to have the registration statement declared effective within (a) 75 calendar days after the closing date, or (b) if the SEC notifies the Issuer that it will review the registration statement, 120 days following the closing date.  The foregoing descriptions do not purport to be complete and are qualified in their entirety by reference to the full text of the agreements, incorporated by reference as exhibits hereto.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ZYNEXT VENTURES USA LLC

**Signature:** Ravi Yadavar

**Name/Title:** Board of Managers

**Date:** 01/22/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ZYNEXT VENTURES PTE LTD

**Signature:** Tan Sock Kheng

**Name/Title:** Director

**Date:** 01/22/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** ZYDUS LIFESCIENCES LTD

**Signature:** Mukund Thakkar

**Name/Title:** Sr. Vice President, Legal

**Date:** 01/22/2026